menu
    • menu
    [{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Dactinomycin","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Children's Oncology Group \/ Undisclosed"},{"orgOrder":0,"company":"Rasna Therapeutics","sponsor":"Tiziana Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Acquisition","leadProduct":"Dactinomycin","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rasna Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rasna Therapeutics \/ Tiziana Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Rasna Therapeutics \/ Tiziana Life Sciences"},{"orgOrder":0,"company":"NanoSmart Pharmaceuticals","sponsor":"Oncology Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Funding","leadProduct":"Dactinomycin","moa":"DNA","graph1":"Oncology","graph2":"Preclinical","graph3":"NanoSmart Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NanoSmart Pharmaceuticals \/ Oncology Pharma","highestDevelopmentStatusID":"4","companyTruncated":"NanoSmart Pharmaceuticals \/ Oncology Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for 01815_FLUKA

    Menu

    01815_FLUKA

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Children's Oncology Group

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Children's Oncology Group

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dactinomycin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

                            Details : Dactinomycin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Wilms Tumor.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            May 06, 2024

                            Lead Product(s) : Dactinomycin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NanoSmart Pharmaceuticals

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            NanoSmart Pharmaceuticals

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dactinomycin

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Oncology Pharma

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Oncology Pharma Has Provided Initial Funding to NanoSmart Pharmaceuticals for Initial Phases of IND-Enabling A...

                            Details : The licensed technology possesses proprietary technology and intellectual property rights for the development of pharmaceutical drug formulations that are liposomal and/or emulsion-based formulations and that may incorporate Anti-Nuclear Antibodies (ANA)...

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            March 31, 2021

                            Lead Product(s) : Dactinomycin

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Oncology Pharma

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Rasna Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Rasna Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dactinomycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Tiziana Life Sciences

                            Deal Size : $0.6 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Tiziana Life Sciences Acquires a Nanoparticle-Based Formulation Technology for Controlled Delivery of Actinomy...

                            Details : Actinomycin-D from Rasna Therapeutics will expand Tiziana Life Sciences's pipeline. The drug is on the WHO's List of Essential Medicines as the most effective medicines needed in a health system.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : $0.1 million

                            April 24, 2020

                            Lead Product(s) : Dactinomycin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Tiziana Life Sciences

                            Deal Size : $0.6 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth